Reported Late Monday March 13, Reunion Neuroscience Files Lawsuit Against Mindset Pharma Alleging That Mindset Knowingly Copied Reunion’s RE104 Compound And Misleadingly Presented That Exact Composition To The Patent Office As Mindset’s Invention

Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion"

Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, has filed a lawsuit today against Mindset Pharma Inc. (“Mindset”) in the United States District Court for the District of New Jersey, alleging that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset’s invention while applying for U.S. Patent No. 11,591,353 (“‘353 Patent”). Reunion thus seeks to add the original and sole inventor of Reunion’s RE104 — Dr. Nathan Bryson, Reunion’s Chief Scientific Officer — as an inventor of the ‘353 Patent. Reunion additionally asserts claims for, among others, co-ownership of the ‘353 Patent, inequitable conduct in the prosecution of the ‘353 Patent, and breach of contract. The complaint can be accessed here.

Reunion is proud of its inventions to further its mission to improve the lives of patients and families who suffer from depression and other mental health disorders and intends to vigorously protect its intellectual property position to the fullest extent.

Related Posts